Outcomes of holmium laser enucleation of the prostate (HoLEP) for very large-sized benign prostatic hyperplasia (over 150 mL): open simple prostatectomy is dead

IntroductionOur study aimed to describe the outcomes of transurethral enucleation of the prostate (HoLEP) for large-sized benign prostatic hyperplasia over 150 mL (bBPH).MethodsWe conducted a retrospective, descriptive, and analytical study of patients undergoing HoLEP for bBPH. The primary endpoint was the success of the procedure, defined by a mixed criteria: complete endoscopic enucleation of the prostate, absence of blood transfusion or reoperation for bleeding, post-operative improvement of quality of life (assessed by a & GE; 2 points increase at in the 8th question of the IPSS test) and post-operative continence (no pads use) at 3 months.ResultsEighty-one patients were included with a mean age of 73.9 & PLUSMN; 7.3 and a mean measured prostate volume of 183.3 & PLUSMN; 34.5 cc. The mean operative time was 57.5 & PLUSMN; 29.7 min and the average wet weight of resected tissue removed was 151.8 & PLUSMN; 44.7 g. Mean hospitalization stay was 1.3 & PLUSMN; 0.7 days with a mean post-operative catheterization period of 1.9 & PLUSMN; 0.9 days. The success of the surgery was achieved in 77 patients (95%). Functional improvements were found at 1 and 6 months for Qmax, post-void residual, IPSS and QoL-IPSS. The 30-day complication rate was 9.9%. The average PSA level dropped from 14.8 & PLUSMN; 11.6 ng/mL at baseline to 0.8 & PLUSMN; 0.5 ng/mL at 6 months.ConclusionHoLEP for bBPH is both safe and efficient. Regarding the benefit/risk balance, it should be highlighted as the gold standard for the management of big BPH.